CD82 (Cluster of Differentiation 82), orKAI1, is a humanprotein encoded by theCD82gene.[5]
Thismetastasis suppressor gene product is a membraneglycoprotein that is a member of thetetraspanin/transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.[5]
^Imai T, Kakizaki M, Nishimura M, Yoshie O (August 1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82".Journal of Immunology.155 (3):1229–39.doi:10.4049/jimmunol.155.3.1229.PMID7636191.S2CID32942467.
^Timologou A, Zafrakas M, Grimbizis G, Miliaras D, Kotronis K, Stamatopoulos P, Tarlatzis B (February 2016). "Immunohistochemical expression pattern of metastasis suppressors".European Journal of Obstetrics & Gynecology and Reproductive Biology.199:110–115.doi:10.1016/j.ejogrb.2016.02.004.PMID26918694.
Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, et al. (November 1992). "C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63".Journal of Immunology.149 (9):2879–86.doi:10.4049/jimmunol.149.9.2879.PMID1401919.S2CID21935007.
Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, et al. (June 1992). "Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11".Cancer Research.52 (12):3486–90.PMID1596907.
Gaugitsch HW, Hofer E, Huber NE, Schnabl E, Baumruker T (February 1991). "A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23".European Journal of Immunology.21 (2):377–83.doi:10.1002/eji.1830210219.PMID1842498.S2CID423800.
Ichikawa T, Ichikawa Y, Isaacs JT (July 1991). "Genetic factors and suppression of metastatic ability of prostatic cancer".Cancer Research.51 (14):3788–92.PMID2065333.
Imai T, Kakizaki M, Nishimura M, Yoshie O (August 1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82".Journal of Immunology.155 (3):1229–39.doi:10.4049/jimmunol.155.3.1229.PMID7636191.S2CID32942467.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".Gene.138 (1–2):171–4.doi:10.1016/0378-1119(94)90802-8.PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".Gene.200 (1–2):149–56.doi:10.1016/S0378-1119(97)00411-3.PMID9373149.
Ono M, Handa K, Withers DA,Hakomori S (December 2000). "Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, alpha5-CD82 glycosylation complex in ldlD 14 cells".Biochemical and Biophysical Research Communications.279 (3):744–50.Bibcode:2000BBRC..279..744O.doi:10.1006/bbrc.2000.4030.PMID11162423.
